New combo attack on tough lung cancer
NCT ID NCT04748419
Summary
This early-stage study is testing whether adding a short, focused course of radiation (a 'boost') to a standard immunotherapy drug (durvalumab) is safe and can help control stage III non-small cell lung cancer. The treatment is given after patients finish their initial chemo-radiation therapy. The main goals are to check for side effects and see if this combination keeps the cancer from growing for longer than expected.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.